Fibroblast growth factor receptor‐1 as a potential therapeutic target in sinonasal cancer. Issue 9 (1st February 2014)

• Record Type: Journal Article
• Authors: Schröck, Andreas; Göke, Friederike; Wagner, Patrick; Bode, Maike; Franzen, Alina; Huss, Sebastian; Agaimy, Abbas; Ihrler, Stephan; Kirsten, Robert; Kristiansen, Glen; Bootz, Friedrich; Lengerke, Claudia; Perner, Sven
• Is Part Of: Head & neck. Volume 36:Issue 9(2014:Sep.)
• Page Start: 1253
• Page End: 1257
• Publication Date: 2014-02-01
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23443
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="hed23443-sec-0001" sec-type="section"> <title>Background</title> <p>Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (<italic>FGFR1</italic>) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer.</p> </sec> <sec id="hed23443-sec-0002" sec-type="section"> <title>Methods</title> <p>One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for <italic>FGFR1</italic> copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker.</p> </sec> <sec id="hed23443-sec-0003" sec-type="section"> <title>Results</title> <p> <italic>FGFR1</italic> amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same <italic>FGFR1</italic> amplification status as the corresponding primary tumor tissue. None of the <italic>FGFR1</italic>‐amplified tumors expressed p16.</p> </sec> <sec id="hed23443-sec-0004" sec-type="section"> <title>Conclusion</title> <p> <italic>FGFR1</italic> amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. <italic>Head Neck</italic> 36: 1253–1257, 2014</p> </sec> </abstract>